Shopping cart processing ...
Your cart0
Products 0
Price $0.00
Bestsellers Pill categories
Customer Support 24/7
usa canada USA
uk UK
au AU
Live Chat 24/7
Customer Support 24/7
USA/Canada Toll Free USA
Customer Support 24/7
usacanada USA
uk UK
au AU
We accept
  • Visa
  • MasterCard
  • Amex
  • JCB
Your cart: $0.00 (0 items)

Categories list

Choosing us you get:

  • Reliable supplier
  • Low Internet prices
  • Free bonus pills
  • Discount on all future orders
  • Discreet package
  • SSL secure orders
Worldwide Shipping!


  • Sean Patrick MacDonald Marietta, GA, USA
    Thanks, guys! Got my hands on your Viagra+Cialis pack. Will definitely come back for more. Summer is ahead of us with the new superman sexual adventures! Yeah, these pills make you feel exactly like a superman, even better than you felt when you were 18. My wife’s just so happy, we had like a whole hour of sex and a second erection right after that! Amazing!
More info »


Glycomet is an oral diabetes medicine used to treat type 2 of diabetes.

Brand: Metformin

Availability: In Stock
Average Delivery Time: 9 Days
Exp. Date: May 2024
Package Price Per pill Save Order
Glycomet 500 mg
120 pills - 500 mg $35.99 $0.30 $27.81 Add to cart
90 pills - 500 mg $31.04 $0.34 $16.81 Add to cart
60 pills - 500 mg $25.94 $0.43 $5.96 Add to cart
30 pills - 500 mg $15.95 $0.53 No Add to cart

Product description

Drug Name

Glycomet (Metformin)

Pharmacological action

Oral hypoglycemic drug of biguanide group (dimethylbiguanide). The mechanism of action of metformin is related to its ability to inhibit gluconeogenesis, as well as the formation of free fatty acids and fat oxidation. It increases the sensitivity of peripheral receptors to insulin and glucose utilization by cells. Glycomet (Metformin) does not affect the amount of insulin in blood, but changes its pharmacodynamics by reducing the ratio of bound to free insulin and increasing the ratio of insulin to proinsulin.

Glycomet (Metformin) stimulates glycogen synthesis by acting on glycogen synthetase. Increases transport capacity of all types of membrane glucose transporters. Delays glucose absorption in the intestine.

Reduces triglycerides, LDL, LDLNP. Metformin improves blood fibrinolytic properties by inhibiting tissue-type plasminogen activator inhibitor.

Against the background of metformin administration, the patient's body weight either remains stable or decreases moderately.

Contraindications to use

Acute or chronic metabolic acidosis, diabetic ketoacidosis, diabetic precoma and coma; renal failure, renal dysfunction (CK<60 ml/min); dehydration, severe infection, hypoglycemic shock, which may lead to renal dysfunction; clinically expressed symptoms of acute and chronic diseases that may lead to the development of tissue hypoxia (including cardiac failure, acute myocardial infarction, respiratory failure); use of contrast iodine-containing substances for intravascular administration (including cardiac insufficiency, acute myocardial infarction, hypoxia). including heart failure, acute myocardial infarction, respiratory failure); use of iodine contrast agents for intravascular administration (including during IV urography, IV cholangiography, angiography, CT); acute alcohol intoxication, chronic alcoholism; hypersensitivity to metformin.

Use in pregnancy and lactation

Adequate and strictly controlled safety studies of metformin use in pregnancy have not been conducted. Administration in pregnancy is possible in cases of extreme necessity, when the expected benefits of therapy for the mother exceed the possible risk to the fetus. Glycomet (Metformin) crosses the placental barrier.

Glycomet (Metformin) is excreted in small amounts with breast milk, and the concentration of metformin in breast milk may be 1/3 of the concentration in mother's plasma. Side effects in newborns during breastfeeding against the background of metformin administration have not been observed. However, due to the limited data, its use during breastfeeding is not recommended. The decision to stop breastfeeding should be made taking into account the benefits of breastfeeding and the potential risk of side effects in the child.

Preclinical studies have shown that metformin has no teratogenic effect at doses that are 2-3 times higher than the therapeutic doses used in humans. Glycomet (Metformin) has no mutagenic potential and has no effect on fertility.

Use in elderly patients

Glycomet (Metformin) is not recommended for use in patients over 60 years of age, which is associated with an increased risk of lactic acidosis.

Glycomet (Metformin) active ingredient indications

Type 2 diabetes mellitus (insulin-independent) in ineffective diet therapy and physical activity, in patients with obesity: in adults - as monotherapy or in combination with other oral hypoglycemic agents or with insulin; in children aged 10 years and older - as monotherapy or in combination with insulin.

Dosing regimen

It is taken orally, during or after meals.

The dose and frequency of administration depend on the therapy regimen, the patient's age and the dosage form used.